Daiwa Securities Group’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-258
| Closed | -$10K | – | 1430 |
|
|
2025
Q4 | $10K | Hold |
258
| – | – | ﹤0.01% | 1186 |
|
|
2025
Q3 | $6K | Hold |
258
| – | – | ﹤0.01% | 1192 |
|
|
2025
Q2 | $4K | Hold |
258
| – | – | ﹤0.01% | 1178 |
|
|
2025
Q1 | $5K | Hold |
258
| – | – | ﹤0.01% | 1136 |
|
|
2024
Q4 | $4K | Hold |
258
| – | – | ﹤0.01% | 1180 |
|
|
2024
Q3 | $4K | Hold |
258
| – | – | ﹤0.01% | 1189 |
|
|
2024
Q2 | $2K | Hold |
258
| – | – | ﹤0.01% | 1269 |
|
|
2024
Q1 | $2K | Hold |
258
| – | – | ﹤0.01% | 1280 |
|
|
2023
Q4 | $2K | Hold |
258
| – | – | ﹤0.01% | 1283 |
|
|
2023
Q3 | $2K | Hold |
258
| – | – | ﹤0.01% | 1229 |
|
|
2023
Q2 | $4K | Hold |
258
| – | – | ﹤0.01% | 1205 |
|
|
2023
Q1 | $6K | Hold |
258
| – | – | ﹤0.01% | 1141 |
|
|
2022
Q4 | $5K | Buy |
258
+50
| +24% | +$1.06K | ﹤0.01% | 1159 |
|
|
2022
Q3 | $5K | Hold |
208
| – | – | ﹤0.01% | 1165 |
|
|
2022
Q2 | $5K | Hold |
208
| – | – | ﹤0.01% | 1176 |
|
|
2022
Q1 | $5K | Hold |
208
| – | – | ﹤0.01% | 1179 |
|
|
2021
Q4 | $6K | Hold |
208
| – | – | ﹤0.01% | 1186 |
|
|
2021
Q3 | $5K | Buy |
208
+94
| +82% | +$1.73K | ﹤0.01% | 1183 |
|
|
2021
Q2 | $2K | Hold |
114
| – | – | ﹤0.01% | 1161 |
|
|
2021
Q1 | $3K | Buy |
114
+18
| +19% | +$497 | ﹤0.01% | 1122 |
|
|
2020
Q4 | $3K | Sell |
96
-167
| -63% | -$3.9K | ﹤0.01% | 1100 |
|
|
2020
Q3 | $5K | Hold |
263
| – | – | ﹤0.01% | 1097 |
|
|
2020
Q2 | $4K | Hold |
263
| – | – | ﹤0.01% | 1129 |
|
|
2020
Q1 | $4K | Hold |
263
| – | – | ﹤0.01% | 1125 |
|
|
2019
Q4 | $4K | Hold |
263
| – | – | ﹤0.01% | 1131 |
|
|
2019
Q3 | $3K | Hold |
263
| – | – | ﹤0.01% | 1108 |
|
|
2019
Q2 | $5K | Hold |
263
| – | – | ﹤0.01% | 1104 |
|
|
2019
Q1 | $6K | Buy |
263
+46
| +21% | +$1.02K | ﹤0.01% | 1070 |
|
|
2018
Q4 | $5K | Hold |
217
| – | – | ﹤0.01% | 1060 |
|
|
2018
Q3 | $6K | Hold |
217
| – | – | ﹤0.01% | 1075 |
|
|
2018
Q2 | $6K | Hold |
217
| – | – | ﹤0.01% | 1087 |
|
|
2018
Q1 | $5K | Buy |
+217
| New | +$5.17K | ﹤0.01% | 1078 |
|
Other funds holding TVTX
AC
PA
NAMI
Daiwa Securities Group's TVTX Position: Q1 2026 in Review
Daiwa Securities Group sold out of Travere Therapeutics (TVTX) in Q1 2026, closing a stake of 258 shares — an estimated $10K sold.
Daiwa Securities Group first reported a position in TVTX in Q1 2018 and held it in 32 quarters. The position peaked at $10K in Q4 2025. 261 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Daiwa Securities Group reported no remaining Travere Therapeutics position as of Q1 2026 after selling out during the quarter.
- Daiwa Securities Group sold 258 Travere Therapeutics shares in Q1 2026, an estimated $10K.
- Daiwa Securities Group first reported a position in Travere Therapeutics in Q1 2018 and held it in 32 quarters.
- Daiwa Securities Group's Travere Therapeutics position peaked at $10K in Q4 2025.
- 261 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.